Amylyx's Pivot From Neurodegenerative to Obesity Meets Its First Revenue Deadline

Amylyx Pharmaceuticals reports first-quarter 2026 earnings before market open on Wednesday, May 7th, with analysts expecting a loss of $0.34 per share. The biotech faces a critical inflection point as it navigates life after withdrawing its ALS drug RELYVRIO from the U.S. market in April 2024 following disappointing trial results, leaving investors focused on pipeline progress and the company's strategic path forward. With a strong analyst consensus and the stock trading near recent highs, this report will test whether management's pivot strategy can sustain investor confidence despite the absence of meaningful revenue.

Part 1: Earnings Preview

Amylyx Pharmaceuticals is a Cambridge, Massachusetts-based biopharmaceutical company focused on developing novel treatments for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS) and other central nervous system disorders. Following the withdrawal of its lead product RELYVRIO from the U.S. market in April 2024, the company has shifted to a pipeline-focused strategy centered on earlier-stage clinical programs.

For the first quarter of 2026, analysts expect Amylyx to report a loss of $0.34 per share when it announces results before market open on May 7th. The company most recently reported a loss of $0.30 per share for the fourth quarter of 2025. Year-over-year, the expected Q1 2026 loss of $0.34 represents a 19.05% improvement compared to the $0.42 loss reported in Q1 2025, reflecting the company's efforts to manage cash burn following the RELYVRIO withdrawal.

Pipeline Development Progress stands as the primary focus for this earnings release. With RELYVRIO revenue eliminated, investors will scrutinize updates on the company's earlier-stage programs, particularly any clinical trial milestones, enrollment progress, or data readouts that could validate the post-RELYVRIO strategy. Management commentary on pipeline advancement will be critical to maintaining confidence in the company's long-term value proposition.

Cash Runway and Capital Allocation represents the second key theme. Following the revenue loss from RELYVRIO's withdrawal, Amylyx's cash position and burn rate have become paramount concerns. Investors will closely examine the balance sheet, quarterly cash consumption, and management's guidance on how long current resources can fund operations without additional capital raises. Any discussion of strategic partnerships, licensing deals, or financing plans will significantly impact investor sentiment.

Regulatory and Strategic Positioning rounds out the narrative. With RELYVRIO's European regulatory status previously uncertain and the U.S. market exit complete, investors will look for clarity on any remaining commercial opportunities, potential asset monetization, or strategic alternatives. Management's articulation of the company's repositioning and long-term vision will be essential to justifying the current valuation in the absence of near-term revenue.

Analyst sentiment remains notably bullish despite the operational challenges. With 11 of 12 analysts rating the stock a Strong Buy and a mean price target of $23.30 implying 45% upside from current levels, Wall Street appears to be betting on the pipeline's potential rather than dwelling on RELYVRIO's failure. Recent upgrades from firms including Guggenheim (raising their target to $30) and Stifel Nicolaus (initiating coverage with a $21 target) suggest confidence that Amylyx's earlier-stage programs could deliver meaningful value, though the lack of near-term catalysts makes this a high-risk, high-reward proposition heading into the print.

Part 2: Historical Earnings Performance

Amylyx has demonstrated a pattern of modest earnings performance relative to expectations over the past four quarters. The company beat estimates in three of the last four quarters, with surprises of +6.67% in Q1 2025, +13.95% in Q3 2025, and +3.23% in Q4 2025. The sole miss came in Q2 2025, when the company reported a loss of $0.46 per share against expectations of $0.44, representing a -4.55% surprise.

The magnitude of beats has been relatively contained, ranging from 3% to 14%, suggesting the company has been managing its cost structure in line with analyst models following the RELYVRIO withdrawal. More significantly, the absolute loss per share has been trending favorably, declining from $0.42 in Q1 2025 to $0.30 in Q4 2025—a 29% improvement over three quarters. This trajectory indicates effective expense management as the company transitions from a commercial operation to a pure-play development-stage biotech.

The year-over-year comparison reinforces this positive trend: the Q1 2026 estimate of $0.34 represents a 19% improvement from the $0.42 loss reported in Q1 2025. However, investors should note that this improvement reflects cost-cutting rather than revenue growth, as the company has essentially zero revenue following RELYVRIO's market exit. The consistency of modest beats suggests analysts have recalibrated their models to the new operating reality, making a significant surprise in either direction less likely unless management announces unexpected strategic developments.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Amylyx typically reports earnings before market open, meaning Day 0 represents the first full trading session where investors can react to results, while Day +1 captures follow-through momentum.

Historical price behavior around Amylyx earnings reveals significant volatility, with an average absolute Day 0 move of 4.46% and Day +1 move of 4.73%. The intraday ranges are even more dramatic, averaging 12.34% on Day 0 and 9.60% on Day +1, indicating substantial intraday swings as investors digest results and management commentary.

The directional pattern has been mixed but recently more constructive. The most recent report on March 3, 2026, saw the stock decline 7.78% on Day 0 before rebounding 6.66% on Day +1, suggesting initial disappointment followed by reassessment. Prior to that, the November 2025 report produced a more muted 5.89% Day 0 decline with minimal follow-through. Notably, the March 2025 report—likely reflecting initial market processing of the post-RELYVRIO strategy—generated an 11.63% Day +1 surge after a flat Day 0, the strongest positive reaction in the recent series.

The wide intraday ranges relative to closing moves suggest significant disagreement among investors about how to value the company's pipeline prospects. With both Day 0 and Day +1 average moves approaching 5%, investors should prepare for material price action regardless of whether the company beats or misses the $0.34 consensus estimate. The pattern suggests that management's qualitative commentary on pipeline progress and cash runway may drive price action as much as the headline EPS figure itself.

Part 2.2: Options Market Expected Move

The options market is pricing a 3.70% expected move through the May 15th expiration, implying a range of $15.47 to $16.66. This is notably more conservative than the stock's historical average earnings move of 4.46% on Day 0 and 4.73% on Day +1, suggesting options traders are anticipating a more subdued reaction than the historical pattern would indicate. The 83.28% average implied volatility reflects elevated uncertainty, but the specific expected move for this event appears to discount some of the extreme swings seen in prior quarters, possibly reflecting the market's view that the company's transition story is becoming more established and less likely to produce dramatic surprises.

Part 3: What Analysts Are Saying

Analyst sentiment on Amylyx Pharmaceuticals remains overwhelmingly bullish, with the stock carrying an average recommendation of 4.83 out of 5.0—firmly in Strong Buy territory. The consensus is remarkably concentrated, with 11 of 12 analysts rating the stock a Strong Buy, one analyst maintaining a Hold rating, and zero Sell ratings. This represents one of the most bullish analyst profiles in the biotech sector.

The average price target of $23.30 implies 45% upside from the current price of $16.06, with the range of targets spanning from $19.00 to $34.00. The wide target range reflects differing views on the probability and timeline for pipeline success, but even the most conservative $19.00 target implies 18% upside, suggesting analysts see limited downside risk at current levels.

Analyst sentiment has remained unchanged over the past month, with the same 11 Strong Buy ratings and identical average recommendation of 4.83. This stability suggests analysts are maintaining conviction in their bullish thesis despite the operational challenges and lack of near-term revenue catalysts. The consistency of ratings through recent quarters indicates that Wall Street's positive view is based on longer-term pipeline potential rather than near-term financial performance, making this earnings report more about validating the strategic transition than delivering financial surprises.

Part 4: Technical Picture

The Barchart Technical Opinion rates Amylyx Pharmaceuticals as a Buy with an 88% signal, unchanged from both one week ago and one month ago. This stability in the technical rating suggests the stock has maintained its constructive technical posture heading into the earnings release, though the signal has not strengthened despite the stock's longer-term uptrend.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum is positive but not overwhelming, suggesting some consolidation or digestion of recent gains
• Medium-term (100% Buy): Strong buy signal across the intermediate timeframe reflects solid momentum over the past several weeks to months
• Long-term (100% Buy): Strong buy signal in the longer-term view confirms the stock remains in a sustained uptrend from its 2024 lows

Trend Characteristics: The trend is characterized as Average strength but Weakening direction, suggesting that while the overall uptrend remains intact, momentum has moderated recently and the stock may be vulnerable to a pullback if earnings disappoint.

The stock is currently trading at $16.06, positioned below its 5-day ($16.19), 10-day ($16.41), and 20-day ($16.85) moving averages, indicating short-term weakness or consolidation after a recent peak. However, the stock remains well above its 50-day ($15.40), 100-day ($14.46), and 200-day ($13.20) moving averages, confirming the longer-term uptrend remains intact. This positioning suggests the stock has pulled back from recent highs near $18.60 but maintains support from longer-term trend followers.

The technical setup heading into earnings is mixed: while the longer-term trend remains constructive with the stock trading 22% above its 200-day moving average, the recent pullback below short-term moving averages and the "Weakening" directional signal suggest momentum has stalled. The stock's failure to hold above the $16.85 level (20-day MA) could make it vulnerable to a sharper correction if earnings or guidance disappoint. Conversely, a strong report that addresses pipeline progress and cash runway concerns could provide the catalyst needed to reclaim the $17-$18 range and challenge the $18.60 52-week high. The technical picture suggests investors should watch the $15.40 level (50-day MA) as key support, with a break below potentially triggering a deeper retracement toward the $14.46 level (100-day MA).